Opportunity Information: Apply for PA 13 143
Apply for PA 13 143
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Acute Kidney Injury in Older Adults (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Mar 14, 2013 and posted on Mar 14, 2013.
- Applicants must submit their applications by May 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Public housing authorities/Indian housing authorities County governments Native American tribal governments (Federally recognized) Special district governments Public and State controlled institutions of higher education State governments Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses For profit organizations other than small businesses Others (see text field entitled Additional Information on Eligibility for clarification) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) City or township governments Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity "Acute Kidney Injury in Older Adults (R21)" (PA-13-143) supports early-stage, exploratory research aimed at improving what is known about acute kidney injury (AKI) specifically in older adults, a population in which AKI is increasingly common and often has serious downstream effects. It uses the NIH R21 mechanism, which is designed for developmental projects that are still in the conceptual or pilot phase. The intent is to give investigators room to test new ideas, generate preliminary evidence, and develop novel tools or approaches. Because of that mission, projects can be higher risk than typical grants, as long as the work has a credible path to producing a major advance, such as a breakthrough insight into mechanisms, a new diagnostic or monitoring approach, or a new preventive or therapeutic strategy.
The FOA is broad in scope and welcomes basic, clinical, translational, and outcomes research, as well as work that crosses these boundaries. Proposed studies can use human subjects, animal models, or other appropriate experimental systems depending on the research question. Across these different research types, the common theme is that the work should directly enhance understanding of why AKI happens so frequently in older people, what makes the aging kidney uniquely vulnerable, and what can be done to detect AKI earlier and manage it more effectively to improve real-world outcomes.
The research areas of interest fall into four main categories. First, the FOA encourages studies on the epidemiology, etiology, and risk factors for AKI in older adults. This can include identifying which clinical characteristics, medications, procedures, comorbidities, or care settings increase risk, and clarifying how risk differs in older populations compared to younger adults. Second, it highlights the pathophysiology of AKI in the aging kidney, including how age-related changes in renal structure, vascular function, inflammation, repair capacity, and resilience may alter AKI susceptibility and recovery. A major emphasis here is understanding how AKI in later life contributes to chronic kidney disease (CKD) progression and how it may interact with disease in other organs, reflecting the systemic consequences of kidney injury in frail or medically complex patients.
Third, the FOA calls for work on earlier detection, diagnosis, and monitoring of AKI. This can include development or testing of biomarkers, imaging approaches, physiologic monitoring, clinical decision tools, or methodologies that help clinicians recognize AKI sooner than traditional measures, track its trajectory, or distinguish different AKI subtypes that may respond to different interventions. Fourth, it invites research on prevention, treatment, and management strategies tailored to older patients. The goal is not only to improve short-term clinical endpoints like in-hospital complications and survival, but also to improve long-term outcomes that matter heavily in older populations, including morbidity, mortality, CKD progression, functional independence, and quality of life. In other words, the FOA signals strong interest in interventions and care strategies that reduce the lasting burden of AKI rather than focusing only on acute laboratory changes.
From an administrative standpoint, this is a discretionary grant opportunity in the health domain (CFDA 93.866, Aging Research) administered by the National Institutes of Health. The opportunity was posted March 14, 2013, with an original and final closing date of May 7, 2016, and it was archived June 7, 2016. While the opportunity is no longer open, the details are still useful as a model for how NIH frames AKI-and-aging priorities and as a reference for similar, newer solicitations. The listed award ceiling is $200,000, consistent with the smaller, exploratory nature of an R21-style project, and there is no cost sharing or matching requirement indicated.
Eligibility is intentionally broad and includes many types of U.S. organizations such as state and local governments, public and private institutions of higher education, nonprofits (including 501(c)(3) and other nonprofit categories), small businesses, and for-profit organizations. The FOA also explicitly includes a wide range of mission-driven and capacity-building institutions and communities, such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based and community-based organizations where appropriate. Importantly, non-U.S. entities and foreign institutions are eligible to apply, non-U.S. components of U.S. organizations may participate, and foreign components are allowed under NIH policy, which supports international collaboration when it strengthens the science.
Overall, this FOA is centered on building a stronger evidence base for AKI in older adults, from root causes and biological mechanisms to practical clinical tools and management strategies. The emphasis on exploratory R21 work reflects NIH interest in seeding innovative concepts that can later mature into larger, definitive studies and, ultimately, into evidence-based guidance that improves diagnosis, prevention, and treatment for a rapidly growing older population at high risk of AKI and its long-term consequences.
FAQs: Acute Kidney Injury in Older Adults (R21) (PA-13-143)
What is this NIH funding opportunity about?
This NIH funding opportunity focuses on acute kidney injury (AKI) in older adults. It supports early-stage, exploratory research meant to improve understanding of why AKI is common in older people, why the aging kidney is especially vulnerable, and what can be done to detect AKI earlier and manage it more effectively to improve outcomes.
What grant mechanism does it use?
It uses the NIH R21 mechanism, which is intended for developmental, exploratory projects that are still in a conceptual or pilot phase. The goal is to help investigators test new ideas, generate preliminary evidence, and develop novel tools or approaches.
What kind of projects is the R21 meant to support in this FOA?
The FOA is aimed at early-stage research that may be higher risk than typical grants, as long as there is a credible path to a major advance. Examples of major advances described include breakthrough insights into mechanisms of AKI in older adults, new diagnostic or monitoring approaches, and new preventive or therapeutic strategies.
Is the scope limited to a specific type of research (basic vs. clinical)?
No. The FOA is broad and welcomes basic, clinical, translational, and outcomes research, including projects that cross these boundaries.
Can proposed studies involve human subjects or animal models?
Yes. Proposed studies may use human subjects, animal models, or other appropriate experimental systems, depending on the research question.
What is the central theme across all research areas in this opportunity?
Across research types, the common theme is that the work should directly enhance understanding of AKI in older adults: why it occurs so frequently, what makes the aging kidney uniquely vulnerable, and how earlier detection and improved management can lead to better real-world outcomes.
What research topics are specifically encouraged?
The FOA highlights four main categories: (1) epidemiology, etiology, and risk factors for AKI in older adults; (2) pathophysiology of AKI in the aging kidney; (3) earlier detection, diagnosis, and monitoring of AKI; and (4) prevention, treatment, and management strategies tailored to older patients.
What does the FOA mean by epidemiology, etiology, and risk factors?
This includes work to identify clinical characteristics, medications, procedures, comorbidities, or care settings that increase AKI risk in older adults, and to clarify how risk in older populations differs from risk in younger adults.
What pathophysiology questions does the FOA emphasize for older adults?
It emphasizes age-related changes that may alter AKI susceptibility and recovery, including changes in renal structure, vascular function, inflammation, repair capacity, and resilience. It also stresses understanding how AKI in later life contributes to chronic kidney disease (CKD) progression and how AKI may interact with disease in other organs.
Does the FOA address longer-term consequences of AKI, like CKD?
Yes. A major emphasis is understanding how AKI in later life contributes to chronic kidney disease (CKD) progression and the broader systemic consequences of kidney injury, particularly in frail or medically complex older patients.
What kinds of early detection or monitoring approaches are of interest?
The FOA invites development or testing of biomarkers, imaging approaches, physiologic monitoring, clinical decision tools, or other methodologies that help clinicians recognize AKI sooner than traditional measures, track AKI trajectory, or distinguish AKI subtypes that may respond differently to interventions.
What types of prevention or treatment studies are encouraged?
The FOA encourages prevention, treatment, and management strategies tailored specifically to older patients, with interest in approaches that reduce lasting burden rather than focusing only on acute laboratory changes.
What outcomes does the FOA care about for older adults?
Beyond short-term endpoints like in-hospital complications and survival, the FOA emphasizes long-term outcomes that often matter heavily in older populations, including morbidity, mortality, CKD progression, functional independence, and quality of life.
What is the award ceiling listed for this opportunity?
The listed award ceiling is $200,000, reflecting the smaller, exploratory nature of an R21-style project.
Is cost sharing or matching required?
No cost sharing or matching requirement is indicated.
Which agency administers this opportunity, and what is the program area?
It is administered by the National Institutes of Health (NIH) and is described as a discretionary grant opportunity in the health domain under CFDA 93.866 (Aging Research).
When was this opportunity posted, and is it still open?
The opportunity was posted on March 14, 2013. It had an original and final closing date of May 7, 2016, and it was archived on June 7, 2016. Based on those dates, it is no longer open.
If it is archived, why might it still be useful?
Even though it is no longer open, the description can still be useful as a model for how NIH frames priorities at the intersection of AKI and aging, and as a reference point for similar, newer solicitations.
Who is eligible to apply?
Eligibility is broad and includes many types of U.S. organizations such as state and local governments, public and private institutions of higher education, nonprofits (including 501(c)(3) and other nonprofit categories), small businesses, and for-profit organizations.
Are specific institution types explicitly included?
Yes. The FOA explicitly includes institutions and communities such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American and Native American Pacific Islander Serving Institutions (AANAPISIs). It also notes faith-based and community-based organizations where appropriate.
Are non-U.S. or foreign organizations eligible?
Yes. Non-U.S. entities and foreign institutions are eligible to apply. In addition, non-U.S. components of U.S. organizations may participate, and foreign components are allowed under NIH policy when they strengthen the science.
What is the overall goal or intended impact of the FOA?
The overall goal is to build a stronger evidence base for AKI in older adults, spanning root causes and biological mechanisms through practical tools and management strategies, with the intention that exploratory R21 work can seed innovative concepts that later mature into larger, definitive studies and evidence-based guidance.
Browse more opportunities from the same category: Health
Next opportunity: OVW FY 2013 Tribal Domestic Violence and Sexual Assault Coalitions Program
Previous opportunity: Acute Kidney Injury in Older Adults (R03)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 13 143
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 13 143) also looked into and applied for these:
| Funding Opportunity |
|---|
| Establishing a Center for Public Health Training in Complex Humanitarian Emergencies Apply for CDC RFA GH13 1370 Funding Number: CDC RFA GH13 1370 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement with the Egypt Ministry of Health and Population for Global Disease Detection Activities Apply for CDC RFA GH13 1369 Funding Number: CDC RFA GH13 1369 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Well Integrated Screening and Evaluation for Women Across the Nation (WISEWOMAN) Apply for CDC RFA DP13 1302 Funding Number: CDC RFA DP13 1302 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $2,000,000 |
| Nationwide Program for National and State Background Checks for Direct Patient Access Employees of Long Term Care Facilities and Providers 9th Announcement Apply for CMS 1A1 13 002 Funding Number: CMS 1A1 13 002 Agency: Centers for Medicare Medicaid Services Category: Health Funding Amount: $3,000,000 |
| Surveillance and Response to Avian and Pandemic Influenza by National Health Authorities outside the United States Apply for CDC RFA IP13 1306 Funding Number: CDC RFA IP13 1306 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $400,000 |
| State Offices of Rural Health Grant Program (SORH) Apply for HRSA 13 162 Funding Number: HRSA 13 162 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Introducing or Expanding the Use of Seasonal Influenza Vaccines in Public Health Programs Outside of the United States Apply for CDC RFA IP13 1305 Funding Number: CDC RFA IP13 1305 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $250,000 |
| Developing Research Capacity to Assess Health Effects Associated with Volcanic Emissions and other Environmental Exposures (R01) Apply for RFA EH 13 002 Funding Number: RFA EH 13 002 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| National Center for HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases and Tuberculosis Prevention, Public Health Conference Support Apply for CDC RFA PS13 1305 Funding Number: CDC RFA PS13 1305 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $200,000 |
| National Center for Environmental Health/Agency for Toxic Substances and Disease Registry Public Health Conference Support Program Apply for CDC RFA EH13 1306 Funding Number: CDC RFA EH13 1306 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| NIBIB Biomedical Technology Resource Centers (P41) Apply for PAR 13 144 Funding Number: PAR 13 144 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Development of Animal Models and Related Biological Materials for Research (R21) Apply for PA 13 145 Funding Number: PA 13 145 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Promoting, Strengthening and Enhancing Disease Prevention by Collaboration with Targeted Stakeholders Apply for CDC RFA IP13 1303 Funding Number: CDC RFA IP13 1303 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $220,000 |
| USAID/Vietnam Request for Information (RFI) on Healthy Markets Activity Apply for SOL 486 13 00022 Funding Number: SOL 486 13 00022 Agency: Thailand USAID Bangkok Category: Health Funding Amount: $15,000,000 |
| Cooperative Centers on Human Immunology (U19) Apply for RFA AI 13 016 Funding Number: RFA AI 13 016 Agency: National Institutes of Health Category: Health Funding Amount: $1,750,000 |
| Limited Competition Dominantly Inherited Alzheimer Network (U19) Apply for PAR 13 147 Funding Number: PAR 13 147 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition Biomarkers for Older Controls at Risk for Dementia (BIOCARD) Study (U19) Apply for PAR 13 148 Funding Number: PAR 13 148 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Organizations for Chronic Disease Prevention Apply for CDC RFA DP10 10080401SUPP13 Funding Number: CDC RFA DP10 10080401SUPP13 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $230,000 |
| NIAID Clinical Trial Implementation Grant (R01) Apply for PAR 13 149 Funding Number: PAR 13 149 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIAID Clinical Trial Planning Grant (R34) Apply for PAR 13 150 Funding Number: PAR 13 150 Agency: National Institutes of Health Category: Health Funding Amount: $150,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 13 143", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.